Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.40 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL281067 | 0.89 | SCN9A (0.57) | SCN9ACHRM2ADORA3KCNH2ALDH1A1 | |
| SCHEMBL10288958 | 0.85 | SCN9A (0.58) | SCN9ACHRM2ADORA3KCNH2ALDH1A1 | |
| SCHEMBL15314957 | 0.84 | SCN9A (0.59) | SCN9ACHRM2ADORA3KCNH2ALDH1A1 | |
| SCHEMBL3331170 | 0.84 | SCN9A (0.59) | SCN9ACHRM2ADORA3KCNH2ALDH1A1 | |
| SCHEMBL30364575 | 0.84 | SCN9A (0.59) | SCN9ACHRM2ADORA3KCNH2ALDH1A1 | |
| SCHEMBL3328842 | 0.84 | SCN9A (0.54) | SCN9AALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL383441 | 0.84 | SCN9A (0.54) | SCN9AALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL2307371 | 0.81 | SCN9A (0.63) | SCN9AALDH1A1KMT2APDK2PDK4 | |
| SCHEMBL2308458 | 0.81 | SCN9A (0.51) | SCN9AALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL385128 | 0.80 | SCN9A (0.58) | SCN9AALDH1A1KMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252962-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2013-09-26 | — | — | US | claimed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | claimed |
| US-20170114075-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-04-27 | — | — | US | disclosed |
| US-20170114075-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-04-27 | — | — | US | disclosed |
| US-20170114075-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-04-27 | — | — | US | disclosed |
| US-9458178-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2016-10-04 | — | — | US | disclosed |
| US-9458178-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2016-10-04 | — | — | US | disclosed |
| US-9458178-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2016-10-04 | — | — | US | disclosed |
| EP-2942350-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2015-11-11 | — | — | EP | disclosed |
| EP-2942350-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2015-11-11 | — | — | EP | disclosed |
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2015-10-15 | — | — | US | disclosed |
| US-8263606-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-09-11 | — | — | US | disclosed |
| US-8263606-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-09-11 | — | — | US | disclosed |
| US-8101647-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-01-24 | — | — | US | disclosed |
| US-20110112162-A9 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2011-05-12 | — | — | US | disclosed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | disclosed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | disclosed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | disclosed |
| US-20100099728-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-04-22 | — | — | US | disclosed |
| WO-2010045251-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114075-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | SCN9A 61/4885CHRM2 2348/4885ADORA3 953/4885 |
| US-20130252962-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | SCN9A 61/4885CHRM2 2348/4885ADORA3 953/4885 |
| US-20110112162-A9 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | SCN9A 61/4885CHRM2 2348/4885ADORA3 953/4885 |
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | SCN9A 61/4885CHRM2 2348/4885ADORA3 953/4885 |
| US-20100099728-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | SCN9A 61/4885CHRM2 2348/4885ADORA3 953/4885 |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | SCN9A 61/4885CHRM2 2348/4885ADORA3 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.